The PASTEUR Act of 2026 establishes a novel subscription contract program to incentivize the development and ensure the availability of critical antimicrobial drugs while promoting their appropriate use.
Michael Bennet
Senator
CO
The PASTEUR Act of 2026 aims to combat antimicrobial resistance by creating a novel federal subscription contract program to ensure the availability of critical new antibiotics. This program will provide substantial annual payments to drug sponsors in exchange for guaranteed access to their life-saving medicines. The Act also establishes an advisory group, funds grants for antimicrobial stewardship in healthcare settings, and enhances national surveillance of resistance data.
PASTEUR Act Proposes $6 Billion 'Subscription' Model to Fight Superbugs and Fund New Antibiotics
The PASTEUR Act of 2026 is essentially a massive government-backed insurance policy against the rise of drug-resistant 'superbugs.' Instead of the traditional way we buy drugs—where pharmaceutical companies make money by selling as many pills as possible—this bill creates a 'subscription' model. Under Section 3, the government would pay drug makers a flat annual fee between $75 million and $300 million for access to new, high-priority antibiotics. The goal is to encourage companies to develop treatments for dangerous pathogens that aren't currently profitable to tackle, ensuring that when a patient in your local ICU faces a resistant infection, the right medicine is actually on the shelf.
The Subscription Swap
This bill flips the script on how we pay for medicine. Currently, if a company makes a great new antibiotic that doctors (rightfully) save only for the most desperate cases, that company goes broke because they aren't selling enough volume. Under the 'Novel Antimicrobial Supply Contracts' in Section 3, the Secretary of Health and Human Services would offer 10-year contracts to developers of 'first-in-class' or innovative drugs. For a busy parent or a construction worker, this means the 'break glass in case of emergency' drugs are funded and ready before the emergency happens. However, these payments are offset by the drug's actual sales revenue, meaning the government isn't just cutting a blank check—it's filling the gap to keep these vital production lines open.
Accountability and the Fine Print
It’s not just free money for Big Pharma; the bill attaches some serious strings. To get paid, companies must track and report drug resistance data to the CDC and maintain a 'reliable supply chain.' They also have to follow environmental standards to ensure they aren't dumping antibiotic waste into the water supply during manufacturing. For the average taxpayer, the $6 billion price tag for 2026 is the main point of impact. While that’s a significant investment, the bill aims to reduce the long-term economic burden of antimicrobial resistance, which currently costs the U.S. billions in extended hospital stays and lost productivity.
Stewardship and Your Local Clinic
Beyond the lab, the bill puts money into the clinics where you actually get treated. It allocates 6.5% of the funding for 'Antimicrobial Stewardship' grants. This means your local rural hospital or urgent care center could get federal help to set up better diagnostic tools and training. The idea is to stop the 'just in case' prescribing of antibiotics for viral infections, which is what causes resistance in the first place. By helping doctors in retail clinics and nursing homes use these drugs more wisely, the bill tries to make sure the new medicines we’re spending billions on today actually still work ten years from now.